NCT04010487 is a clinical trial of whole exome sequencing and RNA-sequencing in Adenomyosis, sponsored by Lei Li.

Who is sponsoring NCT04010487?

NCT04010487 is sponsored by Lei Li.

What drugs are being tested in NCT04010487?

Interventions in NCT04010487: whole exome sequencing and RNA-sequencing.

What condition does NCT04010487 study?

NCT04010487 studies Adenomyosis, Endometrial Cancer, Ectopic Endometrial Tissue, Eutopic Endometrium, Genomics, Transcriptomics.

Is NCT04010487 still recruiting?

NCT04010487 is currently status unknown. Last updated 18 July 2019.

Last reviewed 2019-07-18 · How we verify

NCT04010487

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis

Status unknown Last updated 18 July 2019

What this trial tests

trial testing whole exome sequencing and RNA-sequencing in Adenomyosis in 40 participants. Status unknown.

Timeline

16 July 2019

Primary endpoint
1 August 2021

1 August 2021

Quick facts

Lead sponsor	Lei Li
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	16 July 2019
Primary completion	1 August 2021
Estimated completion	1 August 2021
Sites	1 location across China

Drugs / interventions tested

whole exome sequencing and RNA-sequencing

Conditions studied

Adenomyosis — all drugs for Adenomyosis →
Endometrial Cancer — all drugs for Endometrial Cancer →
Ectopic Endometrial Tissue — all drugs for Ectopic Endometrial Tissue →
Eutopic Endometrium — all drugs for Eutopic Endometrium →

Sponsor

Lei Li — full company profile →

Who can join

18 and older, female only, with Adenomyosis or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA) treated at Peking Union Medical College Hospital from July 15, 2017 to July 15, 2019. The formalin fixed paraffin-embedded tissues from patients pathologically diagnosed with adenomyosis during this time period were also included as control specimens. The eutopic endometrium, normal adenomyosis tissue, and EC-AIA tissue were harvested from the FFPE tissue from patients with EC-AIA. The normal eutopic endometrium and normal adenomyosis tissue were obtained by laser microdissection. The driving genes and potential molecular mechanism of EC-AIA will be found by the technology of whole exome sequencing and transcriptomics (RNA-sequencing).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations.
Zhang XZ, Liu H, Chen SR. · · 2020 · cited 109× · PMID 32429086 · DOI 10.3390/cancers12051245
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study.
Chao X, Wu M, Ma S, Tan X, et al · · 2020 · cited 17× · PMID 32249826 · DOI 10.1038/s41598-020-63065-w
Regulatory Genetic Networks by microRNAs: Exploring Genomic Signatures in Cervical Cancer.
Pérez-Plasencia C, Orbe-Orihuela YC, Méndez-Herrera A, Deas J, et al · · 2025 · PMID 40564176 · DOI 10.3390/biomedicines13061457

Verify or expand the search:

Other recruiting trials for Adenomyosis

Currently open trials in the same condition.

NCT07455721 — Central Sensitization in Women With Adenomyosis: Prevalence, Risk Factors, and Therapeutic Failure · active not recruiting
NCT07486622 — Transvaginal Electromechanical Fragmentation and Removal of Large Uterus in a Sealed Bag: The First Group of Clinical St · active not recruiting
NCT06572852 — Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis · recruiting
NCT06364592 — Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis · NA · recruiting
NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting

Other Lei Li trials

Trials by the same sponsor.

NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
NCT06490380 — HRD Status Reference Standard Based on WGS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04010487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lei Li
Last refreshed: 18 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04010487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing